Basal cell hyperplasia and basal cell carcinoma of the prostate: a comprehensive review and discussion of a case with c-erbB-2 expression.
Prostatic basal cell proliferations range from ordinary basal cell hyperplasia (BCH) to florid basal cell hyperplasia to basal cell carcinoma. The distinction between these forms of BCH, including the variant with prominent nucleoli (formerly called atypical BCH), and basal cell carcinoma depends on morphological and immunohistochemical criteria and, in particular, on the degree of cell proliferation. In florid BCH, the proliferation index is intermediate between ordinary BCH and basal cell carcinoma. Immunohistochemistry is also useful for identifying the cell composition of the basal cell proliferations, including the basal cell nature of the cells, their myoepithelial differentiation, and c-erbB-2 oncoprotein expression. Based on the information derived from the literature and on the appearance and follow up of the case presented here, florid BCH might represent a lesion with an intermediate position between ordinary BCH and basal cell carcinoma. However, criteria useful for the identification of those cases with a true precursor nature are not available. In general, basal cell carcinoma is seen as a low grade carcinoma. The immunohistochemical expression of the c-erbB-2 oncoprotein, similar to that seen in breast cancer, might have therapeutic importance.
Montironi
R
R
Section of Pathological Anatomy and Histopathology, Polytechnic University of the Marche Region, School of Medicine, Azienda Ospedaliera Umberto I, Via Conca 71, I-60020 Torrette, Ancona, Italy. r.montironi@univpm.it
Mazzucchelli
R
R
Stramazzotti
D
D
Scarpelli
M
M
López Beltran
A
A
Bostwick
D G
DG
D000368:Aged; D002280:Basal Cell Carcinoma / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D049109:Cell Proliferation; D003937:Diagnosis, Differential; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*
D018719:Erb-b2 Receptor Tyrosine Kinases
Am J Surg Pathol. 1993 Jul;17(7):645-59
7686348
Am J Surg Pathol. 2004 Oct;28(10):1289-98
15371944
Virchows Arch. 2003 Dec;443(6):787-91
14756145
Hum Pathol. 1988 Dec;19(12):1425-33
2461340
Prostate. 1996 Jul;29(1):51-9
8685056
Am J Clin Pathol. 1988 Jan;89(1):49-56
2827457
Am J Surg Pathol. 1992 Dec;16(12):1205-14
1281386
Histopathology. 1992 Feb;20(2):151-5
1559669
Am J Surg Pathol. 2003 Dec;27(12):1523-9
14657711
Hum Pathol. 1998 Dec;29(12):1447-50
9865831
Am J Surg Pathol. 1984 Sep;8(9):699-704
6206734
Histopathology. 1994 Apr;24(4):341-8
7519164
Hum Pathol. 2003 May;34(5):462-70
12792920
Am J Surg Pathol. 2002 Feb;26(2):237-43
11812946